![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19382-19388, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Internal Medicine, Section of Nephrology,
Yale University School of Medicine, New Haven, Connecticut
06520
Received for publication, January 23, 2002, and in revised form, March 12, 2002
We have examined the ability of epidermal growth
factor (EGF)-stimulated ERK activation to regulate Grb2-associated
binder-1 (Gab1)/phosphatidylinositol 3-kinase (PI3K) interactions.
Inhibiting ERK activation with the MEK inhibitor U0126 increased the
EGF-stimulated association of Gab1 with either full-length glutathione
S-transferase-p85 or the p85 C-terminal Src homology
2 (SH2) domain, a result reproduced by co-immunoprecipitation of the
native proteins from intact cells. This increased association of Gab1
and the PI3K correlates with an increase in PI3K activity and greater
phosphorylation of Akt. This result is in direct contrast to what we
have previously reported following HGF stimulation where MEK
inhibition decreased the HGF-stimulated association of Gab1 and p85. In
support of this divergent effect of ERK on Gab1/PI3K association
following HGF and EGF stimulation, U0126 decreased the HGF-stimulated
association of p85 and the Gab1 c-Met binding domain but did not
alter the EGF-stimulated association of p85 and the c-Met binding
domain. An examination of the mechanism of this effect revealed that
the treatment of cells with EGF + U0126 increased the tyrosine
phosphorylation of Gab1 as well as its association with another
SH2-containing protein, SHP2. Furthermore, overexpression of a
catalytically inactive form of SHP2 or pretreatment with pervanadate
markedly increased EGF-stimulated Gab1 tyrosine phosphorylation. These experiments demonstrate that EGF and HGF-mediated ERK activation result
in divergent effects on Gab1/PI3K signaling. HGF-stimulated ERK
activation increases the Gab1/PI3K association, whereas EGF-stimulated ERK activation results in a decrease in the tyrosine phosphorylation of
Gab1 and a decreased association with the PI3K. SHP2 is shown to
associate with and dephosphorylate Gab1, suggesting that EGF-stimulated ERK might act through the regulation of SHP2.
Grb2-associated binder-1
(Gab1)1 has been identified
in many cell types and appears to play a central role in multiple
cell responses including proliferation, migration, tubulogenesis,
cellular transformation, and apoptosis (1-6). Structural and
functional studies suggest that Gab1 is a multisubstrate-docking
protein functioning downstream of several receptor signaling pathways including the epidermal growth factor (EGF) receptor (EGFR), c-met, and
the insulin receptor tyrosine kinases as well as cytokine receptors
such as the gp130-associated interleukin-6 receptor and T and B
cell antigen receptors (7-10). Similar to the Drosophila daughter of sevenless protein, DOS, and the insulin receptor substrate proteins 1 and 2 family, Gab1 consists of a PH domain at its N terminus, several proline-rich motifs in the C-terminus, and multiple tyrosine phosphorylation sites. But Gab1 is unique in that it contains
a c-met binding domain (MBD) that includes the 13 amino acid c-met
binding sequence, which mediates direct association with c-met (1, 11).
The MBD also mediates indirect association with the activated EGFR via
its proline-rich association with the SH3 domain of Grb2 (2, 11, 12).
The PH domain has been found to be important for Gab1 localization and
epithelial cellular morphogenesis in Madin-Darby canine kidney cells
(5), whereas neoplastic transformation in SHE cells has been
found to correlate with the loss of this domain (3).
Following ligand binding, Gab1 associates with activated c-met or EGFR
and is phosphorylated on specific tyrosine residues, in turn recruiting
a series of SH2 domain-containing proteins that initiate intracellular
signaling cascades. One of the most important signaling proteins found
to associate with Gab1 in response to various stimuli is the
phosphoinositide 3-kinase (PI3K). Studies have shown that the
activation of the PI3K is involved in a wide range of cellular
responses including cell proliferation, differentiation, and prevention
of apoptosis (13-15). We have previously demonstrated that the PI3K is
required for HGF-mediated kidney epithelial cell migration and in
vitro tubulogenesis (16). The importance of Gab1 for this response
has been demonstrated in work by Maroun et al. (5) who found
that the loss of association of Gab1 and the PI3K due to mutation of
the PI3K binding sites in Gab1 results in a decrease of c-met-mediated
tubulogenesis in Madin-Darby canine kidney cells. An association of the
PI3K with Gab1 was also reported to be required for HGF-mediated cell
survival and DNA repair (17).
Previously, it was believed that regulation of the PI3K association
with Gab1 was mediated solely by receptor-dependent
tyrosine phosphorylation of Gab1 on the PI3K SH2 binding motifs
447YVPM451 and
472YVPM476 in the MBD domain, and/or
589YVPM at the carboxyl terminus. However, we have
demonstrated that in addition to tyrosine phosphorylation, Gab1 is also
phosphorylated on serine and threonine in response to ERK2 activation
by HGF (12). In vitro phosphorylation studies revealed that
ERK2 primarily phosphorylates Gab1 in the MBD domain, and an
examination of the Gab1 sequence for potential ERK binding and
phosphorylation sites revealed that the
476TP478 motif immediately following the
472YVPM476 PI3K binding site was a high
probability ERK1/2 phosphorylation site within the MBD domain of Gab1.
In a more recent study, we found that the phosphorylation of both
Tyr472 and Thr476 resulted in a higher
affinity of a YVPMTP-containing peptide for the PI3K than did the
phosphorylation of Tyr472 alone. Thus, ERK1/2-mediated
phosphorylation of this site can initiate a novel regulation of the
Gab1/PI3K interaction. This was confirmed by demonstrating that
HGF-stimulated association of the PI3K with Gab1 was partially
dependent on ERK activation (7).
Our recent determination that HGF-stimulated epithelial cell
morphogenesis requires ERK1/2 activation provides a potential physiologic role for ERK-regulated PI3K activation (18). Interestingly, in this same study, we found that EGF, but not HGF, activates ERK5 in
addition to ERK1/2. The expression of a kinase-dead form of ERK5 in
epithelial cells prevented EGF-stimulated morphogenesis, demonstrating
that EGF and HGF use different MAPK signaling pathways for their
morphogenic responses. Because the branching morphogenesis observed
following EGF and HGF stimulation is phenotypically distinct, we
decided to investigate the effects of EGF-stimulated ERK activation on
the association of Gab1 with the PI3K. In contrast to the positive regulation of the Gab1/PI3K interaction that we found following HGF-stimulated ERK activation, EGF-stimulated ERK activation
down-regulates the interaction of Gab1 and the PI3K. The investigation
of the mechanism of this effect revealed that EGF-stimulated tyrosine phosphorylation of Gab1 was diminished in the setting of ERK
activation, thereby decreasing the association of SH2-docking proteins.
Cell Culture and Reagents--
Immortalized mIMCD-3 epithelial
cells (19) and HEK cells were maintained at low passage using standard
cell culture techniques in Dulbecco's modified Eagle's medium/F-12
containing 10% fetal bovine serum. Experiments were performed when the
cells were 80-90% confluent. All reagents were obtained from Sigma
unless otherwise noted.
EGF Stimulation and MEK Inhibition--
mIMCD-3 cells were
serum-starved for 24 h in Dulbecco's modified Eagle's
medium/F-12 and then stimulated with EGF (20 ng/ml, Sigma), HGF (40 ng/ml, Sigma), or vehicle control for 10 min. To inhibit ERK
activation, cells were pretreated with 10 µM U0126 (Promega) for 20 min prior to EGF stimulation (7). U0126 has been shown
to inhibit MEK1, MEK 2 (20), and MEK5 (18) at concentrations less than
50 µM, but it does not inhibit MEK3, MEK4, MEK6, MEK7, protein kinase C GST Fusion Protein Expression and Pull-down Assay--
The
GST-p85 full-length N-terminal and C-terminal fusion proteins were
expressed as described previously (7, 12). The bacteria were lysed with
sodium deoxycholate, and the supernatants were collected and incubated
with a 50% slurry of glutathione-Sepharose 4B (Amersham Biosciences).
The beads were washed and resuspended in 50 mM HEPES, pH
7.4, 150 mM NaCl, 5 mM dithiothreitol, 5%
glycerol, and 1 µg/ml leupeptin until use. Control experiments were
performed with GST-Sepharose beads generated by expression of the empty pGEX-4T vector. Total GST fusion protein amounts were estimated visually using Coomassie Blue-stained SDS-PAGE with albumin standards. 1 mg of total protein from the appropriate mIMCD-3 whole cell lysates
was then incubated with the GST fusion protein of interest for 30 min
at 4 °C. The glutathione beads were washed three times with ice-cold
lysis buffer followed by resolution through SDS-PAGE. Proteins
were electrophoretically transferred onto Immobilon-P transfer
membranes (Millipore) using Trans-Blot SD semi-dry transfer cell (Bio-Rad) for 90 min at 18 volts. Usually, membranes were blocked
for 1 h at room temperature with 5% nonfat dry milk in wash
buffer containing 10 mM Tris, pH 7.5, 100 mM
NaCl, and 0.1% Tween 20 (TBS-T). After five additional rinses with
TBS-T, blots were incubated with the appropriate primary antibody (Gab1
or p85, Upstate Biotechnology). After rinsing with TBS-T, membranes were incubated with horseradish peroxidase-conjugated secondary antibody at 1:5000 dilution in TBS-T for 60 min at room temperature. Blots were visualized by ECL system (Amersham Biosciences).
Co-immunoprecipitation and Western Blotting--
800 µg of
mIMCD-3 cell lysates were precleared for 1 h at 4 °C with
protein A-Sepharose CL 4B (1:1 slurry in phosphate-buffered saline
(Amersham Biosciences) and centrifuged at 5000 rpm for 2 min at
4 °C. Supernatants were incubated with anti-Gab1 overnight followed
by the addition of protein A-Sepharose CL4B. After incubating for
another 2 h at 4 °C, samples were centrifuged at 5000 rpm for 2 min at 4 °C and washed three times with 0.5 ml of ice-cold lysis
buffer prior to the resolution through SDS-PAGE. Western blot was
performed using the methods mentioned above or following the protocol
of the primary antibody manufacturer. For the expression of the MBD
domain of Gab1, lysates from mIMCD-3 cells transiently transfected with
FLAG-MBD or vector control were used. Transfections were performed with
LipofectAMINE 2000 (Invitrogen) as described previously (7, 12).
Lysates were immunoprecipitated with anti-FLAG antibody (Sigma) as
noted above.
For the expression of SHP2, HEK cells were transiently transfected with
either the empty control vector, pIRES-GFP, or the vector encoding
Myc-tagged wild-type SHP2 (SHP2-WT) or catalytically inactive
SHP2 (SHP2-CS). These constructs, which independently express green
fluorescent protein to allow rapid determination of transfection
efficiency, were a kind gift of Dr. Anton Bennett. Cells were
transfected using calcium phosphate as previously described HGF
(12).
Gab1-associated PI3K Activity Assay--
Immunoprecipitation of
Gab1 from control and EGF-stimulated mIMCD-3 cells ± U0126 was
performed as above. Immunoprecipitates were collected by centrifugation
and washed twice with phosphate-buffered saline containing 1% Nonidet
P-40 and 100 µM Na3VO4, twice
with 100 mM Tris, 500 mM LiCl2, 100 µM Na3VO4, pH 7.5, and twice with 10 mM Tris, 100 mM NaCl, 1 mM EDTA,
and 100 µM Na3VO4, pH 7.5. The
pellets were then resuspended in 50 µl of the final wash buffer containing 12 mM MgCl2 and 20 µg of
phosphatidylinositol (Avanti Polar Lipids, Inc.). To start the PI3K
reaction, 10 µl of 40 µM ATP containing 30 µCi of
[32P]ATP was added to each pellet and was allowed to
incubate at room temperature for 10 min. The reaction was stopped by
the addition of 20 µl of 8 M HCl and the lipids extracted
using 160 µl of CHCl3:MeOH (1:1). The phases were
separated by centrifugation, and 50 µl of the lower organic phase was
spotted onto a glass-backed silicon thin-layer chromatography plate.
The lipids were resolved by thin-layer chromatography in
MeOH-CHCl3-H2O-NH4OH (60:47:11.3:2)
and visualized using the Storm PhosphorImager. Quantitation was
performed on triplicate samples using ImageQuant software.
Statistical Analysis--
All experiments were repeated on at
least three separate occasions. Quantification of ECL immunoblots was
performed using the NIH Image program. The values for
co-immunoprecipitation experiments were normalized to the amount of
immunoprecipitated protein and expressed as the mean ± S.E. The
results were analyzed using the Student's t test. A value
of p < 0.05 was considered significant.
EGF-dependent ERK Activation Decreases EGF-stimulated
Gab1/PI3K Association--
Our observation that HGF
and EGF appear to use different ERK signaling pathways for epithelial
morphogenesis (18) led us to examine the effect of ERK activation on
EGF-stimulated Gab1/PI3K association. Initial experiments tested the
ability of a bacterially expressed GST fusion protein encoding the
full-length p85 subunit of the PI3K to associate with Gab1 from
EGF-stimulated mIMCD-3 cell lysates. Similar to previous results in
Madin-Darby canine kidney cells (5), EGF stimulation was found to
induce the interaction of Gab1 and p85 in vitro (Fig.
1A, upper panel).
To examine the role of ERK in regulating this association, cells were
pretreated with 10 µM U0126, a concentration of the MEK
inhibitor that prevents both ERK1/2 and ERK5 activation (18).
Inhibition of ERK activation resulted in a marked increase in the
EGF-stimulated association of p85 with Gab1. To determine whether this
effect was specific for the p85 SH2 domain interactions with Gab1, we
used GST fusion proteins encoding the N-terminal SH2 and C-terminal SH2
domains of p85. These pull-down experiments revealed that the
EGF-stimulated interaction of Gab1 and the N-terminal SH2 domain of p85
appears to be ERK activation-independent (Fig. 1A,
middle panel), whereas the association of the C-terminal SH2
domain of p85 with Gab1 increased with the inhibition of ERK activation
(Fig. 1A, lower panel), mimicking the results
obtained with full-length p85.
The effects of EGF-mediated ERK activation on endogenous Gab1/PI3K
interactions were then examined by co-immunoprecipitation from mIMCD-3
cells. Compared with control cells, the interaction of Gab1 and the
PI3K was increased following the EGF stimulation (Fig. 1B).
Consistent with the in vitro pull-down results, this interaction was further increased in the setting of inhibition of ERK
activation. The quantitation of the results from three experiments
revealed that stimulation with EGF resulted in a 9-fold increase in
Gab1/PI3K association, whereas concomitant inhibition of ERK activation
led to an additional 40% increase in the Gab1/PI3K association (Fig.
1C). This result was confirmed in EGF-stimulated HEK cells
(data not shown) and demonstrates that EGF-mediated ERK
activation down-regulates the EGF-stimulated Gab1/PI3K association.
ERK Regulation of EGF-stimulated Gab1/PI3K
Association Occurs Outside of the MBD Domain--
In contrast to the
results now presented for EGF, we have previously found that
HGF-mediated ERK1/2 activation causes an increase in the HGF-stimulated
Gab1/PI3K association. The association of the PI3K with Gab1 occurs
primarily at three consensus YXXM association sites in Gab1
(5, 11). One of these sites, 472YVPMTP479, is
included in the Gab1 MBD domain and also encodes the ERK1/2 consensus
phosphorylation sequence PX(S/T)P. We have shown that the MBD region is the primary target of ERK2 phosphorylation of Gab1
(12) and that dual phosphorylation of the
472YVPMTP478 motif on Tyr472 and
Thr476 results in a higher affinity binding site for p85
than does phosphorylation on Tyr472 alone (7). Because
inhibition of ERK activation decreases the Gab1/PI3K association as
well as downstream Akt activation by ~50% (Fig.
2A, left panel)
(7), it is likely that HGF-stimulated ERK2 phosphorylation at the
472YVPMTP478 site results in a physiologically
relevant increase in HGF-stimulated PI3K activation.
The current experiments demonstrate that preventing EGF-stimulated ERK
activation results in an increase in the association of Gab1 with p85,
suggesting that HGF and EGF-stimulated ERK activation can mediate
divergent downstream events (Fig. 2A, right
panel). To determine whether the effects of EGF on ERK-regulated
Gab1/PI3K association are also mediated by the MBD of Gab1, we examined the association of the MBD with p85 following HGF or EGF stimulation. The MBD of Gab1 can associate with and be phosphorylated by either the
c-met receptor (directly through the c-met binding sequence and
indirectly through association with Grb2) or the EGFR (indirectly through association with Grb2).
Immunoprecipitation of the epitope-tagged MBD domain reveals that both
HGF and EGF can induce the association of the Gab1 MBD with the p85
subunit of the PI3K (Fig. 2B, lanes 3 and
5). In agreement with our previous finding that
HGF-stimulated ERK1/2 activation results in the creation of a higher
affinity p85 binding site, U0126 treatment caused a decrease in the
HGF-stimulated MBD-p85 association that was indistinguishable from that
seen with full-length Gab1 (Fig. 2, compare A, lanes
3 and 4, with B, lanes 3 and
4). However, the inhibition of ERK activation did not
influence EGF-induced p85 binding to the Gab1 MBD (Fig. 2B, lanes 5 and 6). Interestingly, the HGF-stimulated
association of p85 with the Gab1 MBD was significantly stronger than
that observed for EGF stimulation, possibly because the dual binding interaction between the MBD and c-met results in a more efficient tyrosine phosphorylation of the p85 binding motif. Taken together, these results are most consistent with a model in which HGF-mediated ERK2 activation increases the Gab1/PI3K association through direct phosphorylation of the p85 binding site in the MBD, whereas
EGF-mediated ERK activation decreases the Gab1/PI3K association through
a mechanism outside of the MBD.
ERK Activation Decreases EGF-mediated Gab1 Tyrosine
Phosphorylation--
Because p85 association is dependent on the
phosphorylation of the YXXM SH2 binding sites in Gab1, the
tyrosine phosphorylation state of Gab1 in both resting and
EGF-stimulated mIMCD-3 cells was examined. Immunoprecipitation with
anti-phosphotyrosine followed by blotting with anti-Gab1 revealed the
expected increase in tyrosine phosphorylation of Gab1 following EGF
stimulation with a further increase in the setting of concomitant
inhibition of ERK activation (Fig.
3A).
Immunoprecipitation of Gab1 followed by
anti-phosphotyrosine immunoblotting confirmed these results (Fig.
3B) with quantitation demonstrating that inhibition of ERK
activation resulted in a 62% increase in the EGF-stimulated tyrosine
phosphorylation of Gab1 (Fig. 3C). In contrast, we have
previously demonstrated that HGF-stimulated ERK1/2 activation does not
alter c-met-mediated Gab1 tyrosine phosphorylation (7).
To investigate whether the increased Gab1 tyrosine phosphorylation,
which occurs following EGF stimulation, and concomitant ERK inhibition
increases the association of Gab1 with other SH2 domain-containing
signaling proteins, we examined the association of Gab1 with SHP2. SHP2
is an SH2 domain-containing tyrosine phosphatase that associates with
Gab1 in a phosphorylation-dependent manner at tyrosines 627 and 659 in the C terminus of Gab1 (8, 21, 22). In both anti-Gab1 and
anti-SHP2 immunoprecipitates, we were able to detect the association of
Gab1 with SHP2 following the stimulation of mIMCD-3 cells with EGF
(Fig. 3D). After inhibition of ERK activation with U0126,
there was a substantial increase in the EGF-stimulated
co-immunoprecipitation of Gab1 and SHP2, similar to that seen with
Gab1/PI3K association. These results demonstrate that EGFR activation
in the absence of ERK activation results in a higher level of tyrosine
phosphorylation of Gab1 and subsequently a greater recruitment of SH2
domain-containing proteins such as the PI3K and SHP2, and they suggest
that EGF-stimulated ERK activation normally serves to down-regulate
Gab1 signaling.
ERK Inhibition Does Not Alter EGFR Phosphorylation or
EGFR·Grb2·Gab1 Complex Formation--
Two potential
mechanisms, whereby EGF-stimulated ERK activation could decrease the
tyrosine phosphorylation state of Gab1, are to either decrease the
EGFR-dependent tyrosine phosphorylation of Gab1 or to
increase the activity of a Gab1-associated phosphatase. A decrease in
the EGFR-dependent tyrosine phosphorylation of Gab1 could
occur because of the inhibition of the EGFR tyrosine kinase activity or
a decrease in the association of Gab1 with the EGFR. As a marker for
EGFR tyrosine kinase activity, we examined the tyrosine phosphorylation
state of the EGFR after stimulation with EGF. Anti-phosphotyrosine
immunoblots of anti-EGFR immunoprecipitates revealed an
indistinguishable level of EGFR phosphorylation in cells stimulated
with EGF in the presence or absence of ERK inhibition with U0126 (Fig.
4A).
The association of Gab1 with the EGFR occurs indirectly via an
SH3-mediated association of Gab1 and Grb2 and a
phosphotyrosine-dependent SH2-mediated association of Grb2 with
the EGFR. Because ERK2 has been shown to directly phosphorylate Gab1 in
the MBD region that encodes one of the proline-rich Grb2 SH3 binding
sites (11), we examined the effects of EGF-stimulated ERK activation on
Gab1·Grb2 and Grb2·EGFR complex formation. The SH3-mediated
association of Gab1 and Grb2 was found to be constitutive and was not
altered by EGF stimulation, either in the presence or absence ERK
inhibition (Fig. 4B). The SH2-mediated association of Grb2
with the EGFR was increased following EGF stimulation with no
alteration detected in the setting of ERK inhibition (Fig.
4C). These results demonstrate no detectable effect of ERK
activation on EGFR phosphorylation or association of the receptor with
Gab1 and thus do not support the model that the EGF-stimulated
ERK-dependent decrease in Gab1 tyrosine phosphorylation is
the result of regulation of the EGFR-mediated tyrosine phosphorylation
of Gab1.
EGF Stimulates SHP2-dependent Dephosphorylation of
Gab1--
An alternative explanation for the ERK-mediated decrease in
EGF-stimulated tyrosine phosphorylation of Gab1 is that ERK serves to
either recruit and/or activate a tyrosine phosphatase to Gab1. To
examine this possibility, we determined the tyrosine phosphorylation state of Gab1 in the presence of the cell-permeable phosphatase inhibitor pervanadate. The addition of pervanadate at 50 µM to serum-starved mIMCD-3 cells resulted in a 4-fold
increase in basal Gab1 tyrosine phosphorylation (Fig.
5A, quantitated in
B). Stimulation with EGF increased the level of tyrosine
phosphorylation 9-fold over base line with an additional 2.2-fold
increase in phosphorylation in the setting of pervanadate treatment.
These data demonstrate that one or more phosphatases regulate the
tyrosine phosphorylation state of Gab1 both in quiescent and
EGF-stimulated cells.
A logical candidate for an EGF-dependent ERK-stimulated
Gab1 tyrosine phosphatase is SHP2. Recently, Gab1 has been identified as a potential SHP2 substrate in the EGF (8) and cytokine receptor signaling pathways (10). In the work by Cunnick et al. (8), SHP2 was found to be capable of dephosphorylating peptides
containing either phosphorylated Tyr589 (a PI3K binding
site in Gab1) or Tyr627 + Tyr659 (the SHP2
binding sites in Gab1), although the ability of SHP2 to dephosphorylate
native Gab1 following EGF stimulation was not determined. To further
examine the role of SHP2 in Gab1 dephosphorylation, we used the
transient expression of SHP2-CS in HEK cells. In unstimulated cells,
the expression of SHP2-CS resulted in a minimal increase in the
tyrosine phosphorylation of Gab1 as compared with cells expressing
wild-type SHP2 or the empty vector (Fig. 5C, lane
2 versus lanes 1 and 3). However, following
EGF stimulation, SHP2-CS-expressing cells exhibited approximately a
2-fold increase in tyrosine phosphorylation compared with controls, a
change similar to that seen following pervanadate treatment (Fig.
5A) or U0126 treatment (Fig. 3B). Of note, we
have thus far been unable to detect an increase in SHP2 phosphatase
activity in Gab1 immunoprecipitates from EGF-stimulated cells using the
artificial substrate paranitrophenyl phosphate, preventing us from
directly determining the role of ERK activation in the regulation of
SHP2. Based on the results shown in Fig. 5A, we believe that
this failure to detect increased SHP2 activity is because of
either the relative insensitivity of the assay or the instability of
the Gab1/SHP2 association.
Our present data are most consistent with a model in which EGF
stimulation results in tyrosine phosphorylation of Gab1 followed by
recruitment of the PI3K and SHP2. SHP2 then acts to dephosphorylate Gab1 and down-regulate its activation, an effect that is enhanced by
simultaneous ERK activation. ERK could be acting to either increase the
association of Gab1 with SHP2 or to stimulate its phosphatase activity.
Our observation that inhibition of ERK activation results in an
increase in the association of Gab1 with SHP2 (Fig. 3D)
would seem to rule out the former possibility. However, it is
conceivable that an initial ERK-mediated increase in SHP2 association results in the dephosphorylation of multiple Gab1 tyrosine residues including Tyr627 and/or Tyr659 followed by the
loss of the SHP2-Gab1 association. Interestingly, the association of
SHP2 with Gab1 through Tyr627 and Tyr659 has
been found to be required for EGF-induced ERK2 activation (8, 22),
suggesting that the ERK-mediated decrease in tyrosine phosphorylation
of Gab1 might then serve as a negative feedback regulator of further
ERK2 activation.
ERK Regulates EGF-stimulated PI3K Activity and Akt
Activation--
The binding of the p85 subunit of the PI3K to
phosphotyrosine residues typically results in the activation of the
catalytic 110kD subunit of the enzyme and the production of
phosphoinositide 3,4,5 triphosphate (PI-3,4,5-P3) at the
cell membrane. To determine whether the increase in the PI3K-Gab1
association detected following the inhibition of ERK activation plays a
significant role in the activation state of the PI3K, PI3K activity was
assayed in anti-Gab1 immunoprecipitates from EGF-stimulated cells. The
stimulation of mIMCD-3 cells with EGF increased the activity of the
PI3K by ~1.5-fold (Fig. 6A).
The pretreatment of EGF-stimulated cells with U0126 resulted in an
additional 2-fold increase in Gab1-associated PI3K activity.
The production of PI-3,4,5-P3 at the membrane serves as a
binding site for PH domain containing proteins such as Akt. The recruitment of Akt to the cell membrane results in its phosphorylation and activation by protein kinase B, leading to enhanced cell survival and proliferation (23). To determine whether ERK regulates the activation of this signaling pathway downstream of the PI3K, we examined the activation of Akt using a phosphorylation-specific antibody. Akt was basally phosphorylated to a low level in control cells with a 1-fold increase in Akt activation following EGF
stimulation (Fig. 6B, quantitated in C). Although
U0126 pretreatment had no effect on basal Akt phosphorylation,
EGF-stimulated cells demonstrated a further 50% increase in Akt
phosphorylation in the setting of U0126-mediated ERK inhibition. These
results demonstrate that EGF-stimulated ERK activation plays a
significant role in down-regulating the ability of Gab1 to recruit and
activate the PI3K and its downstream effectors.
Although both HGF and EGF are capable of activating Gab1 and inducing
epithelial morphogenesis, the phenotypic effects of these growth
factors are distinct. HGF stimulation of mIMCD-3 cells results in cell
processes with multiple branches, whereas the EGFR ligands EGF and
transforming growth factor-
Our results suggest that growth factor-selective MAPK activation is
capable of providing a second level of regulation of the interaction of
the PI3K and Gab1 in addition to receptor phosphorylation of the p85
binding sites. HGF-activated ERK2 appears to directly phosphorylate
Gab1 near the p85 binding site, resulting in enhanced PI3K binding and
activation. In contrast, EGF-stimulated ERK activation, possibly ERK5,
causes a decrease in the tyrosine phosphorylation state of Gab1 and
results in diminished PI3K signaling.
We thank Lucia Rameh for the GST-p85 fusion
protein constructs and Anton Bennett and Maria Kontaridis for the
SHP2 constructs.
*
This work was supported by National Institutes of Health
Grant DK54911 (to L. G. C.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, March 14, 2002, DOI 10.1074/jbc.M200732200
The abbreviations used are:
Gab1, Grb2-associated binder-1;
EGF, epidermal growth factor;
EGFR, EGF
receptor;
PH, pleckstrin homology;
PI3K, phosphatidylinositol 3-kinase;
SH, Src homology;
MAPK, mitogen-activated protein kinase;
PI-3, 4,5-P3, phosphatidylinositol 3,4,5-trisphosphate;
HEK, human embryonic kidney;
TBS-T, Tris-buffered saline with Tween 20;
GST, glutathione S-transferase;
ERK, extracellular
signal-regulated kinase;
MEK, MAPK/extracellular signal-regulated
kinase kinase;
SHP2-WT, wild-type SHP2;
SHP-CS, catalytically
inactive SHP2;
HGF, hepatocyte growth factor.
ERK Negatively Regulates the Epidermal Growth Factor-mediated
Interaction of Gab1 and the Phosphatidylinositol 3-Kinase*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
, protein kinase A, PDK1, or other tested
serine/threonine kinases (20). U0126 was used rather than
PD98059, because we have found that EGF-mediated ERK5
activation, which is critical for EGF-mediated mIMCD-3 cell
morphogenesis, is fully inhibited by U0126 but only partially inhibited
by PD98059 at concentrations
100 µM (18).
Following EGF stimulation, cells were lysed in 800 µl of ice-cold
radioimmune precipitation lysis buffer containing 50 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 2 µg/ml aprotinin,
2 µg/ml leupeptin, 2 µg/ml pepstatin A, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 1 mM
Na3VO4.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 1.
The EGF-stimulated interaction of Gab1 with
p85 is up-regulated by inhibition of ERK activation.
A, bacterially expressed full-length GST-p85
(gst-p85 pulldown, upper panel), N-terminal SH2
domain of p85 (gst-NSH2 pulldown, middle panel)
and C-terminal SH2 domain of p85 (gst-CSH2 pulldown, lower
panel) were used for pull-down experiments of control and
EGF-stimulated mIMCD-3 cell lysates ± pretreatment with U0126 (10 µM). IB:
-Gab, immunoblotting of Gab1.
B, co-immunoprecipitation of Gab1 (IB:
-Gab1)
and p85 (IB:
-p85) from mIMCD-3 cells ± EGF ± U0126. IP:
-Gab1, immunoprecipitation of Gab1.
C, quantitation of the co-immunoprecipitation of Gab1 and
p85, as shown in B, normalized to 1 for EGF stimulation
alone (*, p < 0.01, n = 3).

View larger version (43K):
[in a new window]
Fig. 2.
Differential effects of HGF and EGF-mediated
ERK activation on Gab1/p85 association. A,
serum-starved mIMCD-3 cells were stimulated with HGF or EGF for 10 min ± pretreatment with U0126 followed by immunoprecipitation of
Gab1 (IP:
-Gab1) and immunoblotting with anti-p85
(IB:
-p85, upper panel) or anti-Gab1
(IB:
-Gab1, lower panel). B, the
FLAG-tagged MBD of Gab1 (FLAG-MBD) and empty FLAG-CMV-II
vector (Vector) were transiently transfected into mIMCD-3
cells followed by stimulation with HGF or EGF ± pretreatment with
U0126. Lysates were immunoprecipitated with anti-FLAG
(IP:
-FLAG) and immunoblotted with anti-p85
(IB:
-p85, upper panel). Equal expression of
the FLAG-MBD construct was determined by immunoblotting 20 µg of the
original cell lysate with anti-FLAG (IB:
-FLAG,
lower panel).

View larger version (35K):
[in a new window]
Fig. 3.
Effects of ERK inhibition on the EGF-induced
tyrosine phosphorylation of Gab1. A, mIMCD-3 cells were
stimulated with EGF ± U0126 followed by anti-phosphotyrosine
immunoprecipitation (IP:
-pTyr) and anti-Gab1
immunoblotting (IB:
-Gab1, upper panel). Equal
starting material for the immunoprecipitations is shown by blotting 20 µg of the original cell lysate with anti-Gab1
(IB:
-Gab1, lower panel). B, cells
were plated in triplicate, treated ± EGF ± U0126 followed
by immunoprecipitation of Gab1 (IP:
-Gab1) and
immunoblotting with anti-phosphotyrosine (IB:
-pTyr,
upper panel) and anti-Gab1 (IB:
-Gab1,
lower panel). Experiment was repeated on three separate
occasions, one experiment is shown. C, quantitation of the
experiment, as shown in B, normalized to 1 for EGF
stimulation alone (*, p < 0.001, n = 3). D, immunoprecipitation of Gab1
(IP:
-Gab1, upper panel) or SHP2
(IP:
-SHP2, lower panel) from mIMCD-3 cells
stimulated with EGF ± pretreatment with U0126 followed by
immunoblotting with the alternate antibody. IB:
-SHP2,
immunoblotting of SHP2.

View larger version (32K):
[in a new window]
Fig. 4.
ERK inhibition does not alter
EGFR phosphorylation or EGFR·Grb2·Gab1 complex formation.
mIMCD-3 cells were serum-starved overnight and then stimulated with
EGF ± pretreatment with U0126. A, the EGFR was
immunoprecipitated (IP:
-EGFR), and its phosphorylation
state was determined by immunoblotting with anti-pTyr
(IB:
-pTyr, upper panel). Equal loading
was determined by stripping and re-probing the same membrane with the
antibody to the EGFR (IB:
-EGFR, lower panel).
B, Gab1·Grb2 complex formation was examined by
co-immunoprecipitation of the proteins. IB:
-Gab1,
immunoblotting of Gab1; IB:
-Grb2, immunoblotting of Grb2.
C, cells were treated ± EGF ± U0126 followed by
immunoprecipitation of Grb2 (IP:
-Grb2) and immunoblotting
with either the anti-EGFR antibody (IB:
-EGFR, upper
panel) or with anti-Grb2 (IB:
-Grb2, lower
panel).

View larger version (24K):
[in a new window]
Fig. 5.
Phosphatase-mediated dephosphorylation of
Gab1. A, after overnight serum starvation, mIMCD-3
cells were stimulated with EGF ± pretreatment with pervanadate
(50 µM). Phosphorylation of Gab1 was determined by
anti-Gab1 immunoprecipitation (IP:
-Gab1) followed by
immunoblotting with anti-pTyr (IB:
-pTyr).
IB:
-Gab1, immunoblotting of Gab1. B,
quantitation of these experiments was performed normalized to 1 for EGF
stimulation alone (*, p < 0.01 versus no pervanadate, n = 3). C,
either Myc-tagged SHP2-WT, SHP2-CS, or the empty vector was transiently
expressed in HEK cells. The cells were serum-starved for 6 h
followed by stimulation with EGF or vehicle control. Phosphorylation of
Gab1 was determined by anti-pTyr immunoblotting
(IB:
-pTyr) of anti-Gab1 immunoprecipitates
(IP:
-Gab1) (upper panel). Equal loading was
determined by re-probing the same membrane with anti-Gab1
(IB:
-Gab1, middle panel). Equal expression of
the Myc-tagged constructs was determined by immunoblotting whole cell
lysates with an anti-Myc antibody (IB:
-Myc, lower
panel).

View larger version (22K):
[in a new window]
Fig. 6.
ERK regulates EGF-stimulated PI3K
activity. A, PI3K activity was measured in anti-Gab1
immunoprecipitates from mIMCD-3 cells stimulated with EGF ± U0126. Incorporation of 32P-labeled phosphate into
phosphatidylinositol to form phosphatidylinositol 3-phosphate
(PI3P) was detected by
autoradiography (upper panel) and quantitated (lower
panel), normalized to 1 for control (*,
p < 0.001, n = 3). B,
serum-starved mIMCD-3 cells were stimulated with EGF ± U0126.
Twenty micrograms of whole cell lysates were separated by SDS-PAGE and
were analyzed by anti-phospho-Akt (IB:
-p-Akt, upper
panel), anti-phospho-ERK (IB:
-p-ERK, middle
panel), and anti-total Akt (IB:
-Akt, lower panel).
C, the quantitation of three experiments performed as
described in B (*, p < 0.01, n = 3,).
stimulate longer processes with
fewer branch points (24). The ability of Gab1 to induce these
morphogenic effects is dependent on its localization to the membrane,
which is mediated by the binding of the Gab1 PH domain to
PI-3,4,5-P3 (5). The association of the PI3K with Gab1,
resulting in local PI-3,4,5-P3 generation, thus serves to
perpetuate Gab1 signaling. Therefore, the careful regulation of this
interaction may serve to dictate whether the phenotypic outcome of
receptor stimulation is process branching or process elongation.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of Internal
Medicine, Section of Nephrology, Yale University School of Medicine, 333 Cedar St., LMP 2093, New Haven, CT 06520-8062. Tel.: 203-785-7111; Fax: 203-785-7068; E-mail: chengfang.yu@yale.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Weidner, K. M., Di,
Cesare, S.,
Sachs, M.,
Brinkmann, V.,
Behrens, J.,
and Birchmeier, W.
(1996)
Nature
384,
173-176[CrossRef][Medline]
[Order article via Infotrieve]
2.
Holgado-Madruga, M.,
Emlet, D. R.,
Moscatello, D. K.,
Godwin, A. K.,
and Wong, A. J.
(1996)
Nature
379,
560-564[CrossRef][Medline]
[Order article via Infotrieve]
3.
Kameda, H.,
Risinger, J. I.,
Han, B. B.,
Baek, S. J.,
Barrett, J. C.,
Abe, T.,
Takeuchi, T.,
Glasgow, W. C.,
and Eling, T. E.
(2001)
Mol. Cell. Biol.
21,
6895-6905 4.
Korhonen, J. M.,
Said, F. A.,
Wong, A. J.,
and Kaplan, D. R.
(1999)
J. Biol. Chem.
274,
37307-37314 5.
Maroun, C. R.,
Holgado-Madruga, M.,
Royal, I.,
Naujokas, M. A.,
Fournier, T. M.,
Wong, A. J.,
and Park, M.
(1999)
Mol. Cell. Biol.
19,
1784-1799 6.
Fixman, E. D.,
Holgado-Madruga, M.,
Nguyen, L.,
Kamikura, D. M.,
Fournier, T. M.,
Wong, A. J.,
and Park, M.
(1997)
J. Biol. Chem.
272,
20167-20172 7.
Yu, C. F.,
Roshan, B.,
Liu, Z. X.,
and Cantley, L. G.
(2001)
J. Biol. Chem.
276,
32552-32558 8.
Cunnick, J. M.,
Mei, L.,
Doupnik, C. A.,
and Wu, J.
(2001)
J. Biol. Chem.
276,
24380-24387 9.
Takahashi-Tezuka, M.,
Yoshida, Y.,
Fukada, T.,
Ohtani, T.,
Yamanaka, Y.,
Nishida, K.,
Nakajima, K.,
Hibi, M.,
and Hirano, T.
(1998)
Mol. Cell. Biol.
18,
4109-4117 10.
Nishida, K.,
Yoshida, Y.,
Itoh, M.,
Fukada, T.,
Ohtani, T.,
Shirogane, T.,
Atsumi, T.,
Takahashi-Tezuka, M.,
Ishihara, K.,
Hibi, M.,
and Hirano, T.
(1999)
Blood
93,
1809-1816 11.
Schaeper, U.,
Gehring, N. H.,
Fuchs, K. P.,
Sachs, M.,
Kempkes, B.,
and Birchmeier, W.
(2000)
J. Cell Biol.
149,
1419-1432 12.
Roshan, B.,
Kjelsberg, C.,
Spokes, K.,
Eldred, A.,
Crovello, C. S.,
and Cantley, L. G.
(1999)
J. Biol. Chem.
274,
36362-36368 13.
Frevert, E. U.,
Bjorbaek, C.,
Venable, C. L.,
Keller, S. R.,
and Kahn, B. B.
(1998)
J. Biol. Chem.
273,
25480-25487 14.
Kimura, K.,
Hattori, S.,
Kabuyama, Y.,
Shizawa, Y.,
Takayanagi, J.,
Nakamura, S.,
Toki, S.,
Matsuda, Y.,
Onodera, K.,
and Fukui, Y.
(1994)
J. Biol. Chem.
269,
18961-18967 15.
Leevers, S. J.,
Weinkove, D.,
MacDougall, L. K.,
Hafen, E.,
and Waterfield, M. D.
(1996)
EMBO J.
15,
6584-6594[Medline]
[Order article via Infotrieve]
16.
Derman, M. P.,
Cunha, M. J.,
Barros, E. J.,
Nigam, S. K.,
and Cantley, L. G.
(1995)
Am. J. Physiol.
268,
F1211-F1217[Medline]
[Order article via Infotrieve]
17.
Fan, S., Ma, Y. X.,
Gao, M.,
Yuan, R. Q.,
Meng, Q.,
Goldberg, I. D.,
and Rosen, E. M.
(2001)
Mol. Cell. Biol.
21,
4968-4984 18.
Karihaloo, A.,
O'Rourke, D. A.,
Nickel, C.,
Spokes, K.,
and Cantley, L. G.
(2001)
J. Biol. Chem.
276,
9166-9173 19.
Rauchman, M.,
Nigam, S.,
Delpire, E.,
and Gullans, S.
(1993)
Am. J. Physiol.
265,
F416-F424[Medline]
[Order article via Infotrieve]
20.
Davies, S. P.,
Reddy, H.,
Caivano, M.,
and Cohen, P.
(2000)
Biochem. J.
351,
95-105[CrossRef][Medline]
[Order article via Infotrieve]
21.
Yart, A.,
Laffargue, M.,
Mayeux, P.,
Chretien, S.,
Peres, C.,
Tonks, N.,
Roche, S.,
Payrastre, B.,
Chap, H.,
and Raynal, P.
(2001)
J. Biol. Chem.
276,
8856-8864 22.
Cunnick, J. M.,
Dorsey, J. F.,
Munoz-Antonia, T.,
Mei, L.,
and Wu, J.
(2000)
J. Biol. Chem.
275,
13842-13848 23.
Alessi, D. R.,
Andjelkovic, M.,
Caudwell, B.,
Cron, P.,
Morrice, N.,
Cohen, P.,
and Hemmings, B. A.
(1996)
EMBO J.
15,
6541-6551[Medline]
[Order article via Infotrieve]
24.
Barros, E. J.,
Santos, O. F.,
Matsumoto, K.,
Nakamura, T.,
and Nigam, S. K.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4412-4416
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Kiyatkin, E. Aksamitiene, N. I. Markevich, N. M. Borisov, J. B. Hoek, and B. N. Kholodenko Scaffolding Protein Grb2-associated Binder 1 Sustains Epidermal Growth Factor-induced Mitogenic and Survival Signaling by Multiple Positive Feedback Loops J. Biol. Chem., July 21, 2006; 281(29): 19925 - 19938. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Lee, E. J. Kang, G. Y. Hur, K. H. Jung, H. C. Jung, S. Y. Lee, J. H. Kim, C. Shin, K. H. In, K. H. Kang, et al. Peroxisome proliferator-activated receptor-{gamma} inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L84 - L90. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sithanandam, G. T. Smith, J. R. Fields, L. W. Fornwald, and L. M. Anderson Alternate Paths from Epidermal Growth Factor Receptor to Akt in Malignant Versus Nontransformed Lung Epithelial Cells: ErbB3 Versus Gab1 Am. J. Respir. Cell Mol. Biol., November 1, 2005; 33(5): 490 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gallicchio, S. Mitola, D. Valdembri, R. Fantozzi, B. Varnum, G. C. Avanzi, and F. Bussolino Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor Blood, March 1, 2005; 105(5): 1970 - 1976. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Arnaud, C. Crouin, C. Deon, D. Loyaux, and J. Bertoglio Phosphorylation of Grb2-Associated Binder 2 on Serine 623 by ERK MAPK Regulates Its Association with the Phosphatase SHP-2 and Decreases STAT5 Activation J. Immunol., September 15, 2004; 173(6): 3962 - 3971. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Holgado-Madruga and A. J. Wong Role of the Grb2-Associated Binder 1/SHP-2 Interaction in Cell Growth and Transformation Cancer Res., March 15, 2004; 64(6): 2007 - 2015. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Kapoor, Y. Zhan, G. R. Johnson, and D. M. O'Rourke Distinct Domains in the SHP-2 Phosphatase Differentially Regulate Epidermal Growth Factor Receptor/NF-{kappa}B Activation through Gab1 in Glioblastoma Cells Mol. Cell. Biol., January 15, 2004; 24(2): 823 - 836. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Sundgren, G. D. Giraud, J. M. Schultz, M. R. Lasarev, P. J. S. Stork, and K. L. Thornburg Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2003; 285(6): R1481 - R1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Macdonald, K. Crowder, A. Street, C. McCormick, K. Saksela, and M. Harris The Hepatitis C Virus Non-structural NS5A Protein Inhibits Activating Protein-1 Function by Perturbing Ras-ERK Pathway Signaling J. Biol. Chem., May 9, 2003; 278(20): 17775 - 17784. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Martinez and F. C. A. Gomes Neuritogenesis Induced by Thyroid Hormone-treated Astrocytes Is Mediated by Epidermal Growth Factor/Mitogen-activated Protein Kinase-Phosphatidylinositol 3-Kinase Pathways and Involves Modulation of Extracellular Matrix Proteins J. Biol. Chem., December 13, 2002; 277(51): 49311 - 49318. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Cai, K. Nishida, T. Hirano, and P. A. Khavari Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation J. Cell Biol., October 14, 2002; 159(1): 103 - 112. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||